3-氟-1,2-亚苯基双(3-羟基苯甲酸酯) | 1223397-11-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 缩酚酸和缩酚酸环醚类
• 中文名称: 3-氟-1,2-亚苯基双(3-羟基苯甲酸酯)
• 英文名称: WZB117
• 英文别名: 3-fluoro-1,2-phenylene bis(3-hydroxybenzoate)；[3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate
• CAS: 1223397-11-2
• 化学式: C₂₀H₁₃FO₆
• 分子量: 368.318
• InChiKey: FRSWCCBXIHFKKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为产物：
  描述：

  在 1% Pd/C 、 氢气 作用下， 生成 3-氟-1,2-亚苯基双(3-羟基苯甲酸酯)
  参考文献：
  名称：

  Novel inhibitors of basal glucose transport as potential anticancer agents

  摘要：

  Cancer cells commonly show increased levels of glucose uptake and dependence. A potential strategy for the treatment of cancer may be the inhibition of basal glucose transport. We report here the synthesis of a small library of polyphenolic esters that inhibit basal glucose transport in H1299 lung and other cancer cells. These basal glucose transport inhibitors also inhibit cancer cell growth in H1299 cells, and these two activities appear to be correlated. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.027

文献信息

• Pancreatic cancer therapy and diagnosis
  申请人：Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts

  公开号：US10874685B2

  公开（公告）日：2020-12-29

  The present disclosure provides a novel method for treating pancreatic cancer and pancreatitis in which a combination of a dopamine receptor antagonist (pimozide, haloperidol, and/or L-741,626), 2-deoxy-D-glucose and atorvastatin are used, optionally in combination with gemcitabine.

  本公开提供了一种治疗胰腺癌和胰腺炎的新方法，其中使用多巴胺受体拮抗剂（匹莫齐特、氟哌啶醇和/或 L-741,626）、2-脱氧-D-葡萄糖和阿托伐他汀的组合，可选择与吉西他滨联合使用。
• PANCREATIC CANCER THERAPY AND DIAGNOSIS
  申请人：Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts

  公开号：US20200030356A1

  公开（公告）日：2020-01-30

  The present disclosure provides a novel method for treating pancreatic cancer and pancreatitis. The disclosure pertains to antagonists of dopamine receptors, that when combined with a glycolysis inhibitor, and a cholesterol lowering agent inhibit the growth of pancreatic cells.
• RAPAGLUTINS, NOVEL INHIBITORS OF GLUT AND USE THEREOF
  申请人：The Johns Hopkins University

  公开号：US20210214390A1

  公开（公告）日：2021-07-15

  Compounds with the following structures and their analogs are provided. Compositions that include these structures can be used to inhibit glucose transporters and stop or decrease the proliferation of cancer, treat possible organ rejection and treat autoimmune disease.
• [EN] METHODS FOR PREDICTING OR TREATING MYELOPOIESIS-DRIVEN CARDIOMETABOLIC DISEASES AND SEPSIS<br/>[FR] MÉTHODES PERMETTANT DE PRÉVOIR OU DE TRAITER LA SEPTICÉMIE ET LES MALADIES CARDIOMÉTABOLIQUES INDUITES PAR LA MYÉLOPOÏÈSE
  申请人：INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)

  公开号：WO2017129558A1

  公开（公告）日：2017-08-03

  The present invention relates to a method of treating myelopoiesis-driven cardiometabolic diseases and sepsis in a subject in need thereof comprising the step of administering the subject with a therapeutically effective amount of an agent selected from the group consisting of GLUT1 inhibitors and GOTs inhibitors.
• [EN] A POTENTIAL COMBINATION THERAPY USING AN INHIBITOR OF GLUCOSE TRANSPORT AND AN INTRACELLULAR CALCIUM INDUCER TO TARGET CANCER METABOLISM<br/>[FR] POLYTHÉRAPIE POTENTIELLE UTILISANT UN INHIBITEUR DE TRANSPORT DU GLUCOSE ET UN INDUCTEUR DE CALCIUM INTRACELLULAIRE POUR CIBLER LE MÉTABOLISME DU CANCER
  申请人：NAT UNIV SINGAPORE

  公开号：WO2017180063A1

  公开（公告）日：2017-10-19

  The present invention relates to modulating cancer cell death. More particularly, the present invention relates to methods, compositions and kits for modulating the survival of glucose deprivation-sensitive cancer cells by inhibiting glucose transporters and modulating cytosolic calcium levels.